|
Feb 13
|
Medicenna Therapeutics up 12% Following Third-Quarter Results
|
|
Feb 13
|
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
|
|
Oct 15
|
OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX
|
|
Jan 12
|
Medicenna Announces Appointment of New Auditor
|
|
Jan 9
|
Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab
|
|
Dec 22
|
Medicenna Extends Period to Exercise Certain Warrants
|
|
Dec 19
|
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF
|
|
Oct 3
|
Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy
|